UK Innovators

Submit an Innovation

  • Why File an Innovation Report Form?
    • The Innovation Report Form provides the OTC with basic information about the innovation, allows us to assess patentability and commercial potential, and supports the patent filing decision. As seen below, the process includes 3 easy steps.
    • Once your innovation or discovery has successfully completed all three of these steps, the OTC will begin working with you to commercialize your innovation via an industry license, a startup company, or other means.
    • We strongly encourage innovators to submit an Innovation Report Form before any public disclosures (lecture, posters, presentations, meetings with industry, etc.) that may adversely affect the patentability of an innovation. However, even if you have already disclosed your idea, it is still possible to receive protection, so please contact us anyway!
  • Innovation Reporting in 3 Easy Steps

View Your Innovations

UK Innovators can view past University of Kentucky innovations they are inventors on through the Sophia system. Contact the Intellectual Property/Compliance Coordinator to request access to Sophia.  

Login to the Sophia system using your Linkblue account. 

Access all of your innovation reporting history using OTC's online portal. The portal can be accessed using your Linkblue login. If you have any issues with your innovation account views, please contact the Intellectual Property Coordinator

Income Distribution

Income Distribution Process

License and royalty income derived from the commercialization of UK inventions is distributed according to UK's Administrative Regulations as follows:

  1. Income Received from Licensee
  2. Income Distributed to Inventors (40%)
    • Following payment of patent expenses, distributions occur by the end of December and June of each fiscal year
  3. Income Distributed to Colleges (20%) and Departments (20%)
    • Distributions occur by the end of July and January of each fiscal year

Biological Materials Form

Biological materials such as cell lines, antibodies, plasmids, etc. constitute tangible intellectual property within the scope of UK’s IP Policy (Administrative Regulation 7:6).  Although these materials are not typically patentable, they may be commercialized. 

It is important to complete a new biological materials form to enable us to better understand what the material is, identify who created it, and assess its commercial potential. Additionally, we must be sure to identify any grants or sponsored awards used to support the development of the materials to ensure our compliance with those contracts

To report new biological materials you have developed, please contact the Office of Technology Commercialization to request our Biological Materials Report form.  

Request an MTA/NDA/DUA

Commercialization Process

OTC Technology Commercialization Process

The OTC’s technology commercialization process follows best practices in technology transfer, licensing and new venture development. Utilizing years of successful licensing and start-up experience, our efforts are collaborative with innovator input and involvement. Please reach out to our technology commercialization team to learn more about how we can help accelerate industry adoption of your innovation.

Innovation, Assessment, Commercialization



  • Innovator researches and discovers innovation
  • Innovator discloses innovation to the OTC


  • OTC completes a technology and market assessment of the innovation
  • OTC pursues appropriate IP protection


  • OTC develops and implements a commercialization strategy for licensing the innovation to a start up or to an established company